ImmuPharma plc (LON:IMM – Get Free Report)’s share price traded up 28.8% on Saturday . The company traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). 44,749,293 shares were traded during trading, an increase of 451% from the average session volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).
ImmuPharma Price Performance
The stock has a market cap of £69.86 million, a PE ratio of -1,570.67 and a beta of 1.53. The stock has a 50-day moving average price of GBX 3.12 and a two-hundred day moving average price of GBX 2.91.
ImmuPharma (LON:IMM – Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Equities research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzorâ„¢), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Health Care Stocks Explained: Why You Might Want to Invest
- Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside
- How to Invest in the FAANG Stocks
- Football Season Is Here and DraftKings Stock Is Surging
- Canada Bond Market Holiday: How to Invest and Trade
- RH Stock Slides After Mixed Earnings and Tariff Concerns
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.